Currently, there are no animal models that can be used to test pharmacological efficacy of drugs that are under development for treating dry AMD. We suggest measuring the accumulation of a panel of drusenlike proteins on Bruch's membrane in mice as a surrogate endpoint to test pharmacological modulation of the course of drusen formation. We further suggest that the buildup of proteins on Bruch's membrane in the RPE/choroid in ''smoking mice" can be used as a surrogate model for pharmacological studies and that using these mice will significantly decrease the time frame for demonstrating pharmacological efficacy of lead compounds.
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Age-related Macular Degeneration (AMD) is a major cause of central vision loss in the elderly. In recent years there have been many human genetic studies aimed at finding the causes of AMD. In addition, the goal of much of the laboratory based translational research in the field is to find pharmacological treatments that would be effective against AMD. These efforts have been successful for wet AMD. Currently, there are pharmacological treatments for patients with wet AMD, for example Lucentis, which have proven very successful. Furthermore, many academic and commercial laboratories are working on new pharmacological agents that will stop the neovascularization and vascular leakage associated with wet AMD. Animal models that are used to study ''proof of concept" or efficacy for drugs aimed at wet AMD employ various methods to produce choroidal neovascularization in mice or rats and measure area/volume of retinal neovascularization and/or vascular leakage.
The dry form of AMD, which is characterized by drusen in the macula, is more common than wet AMD and accounts for about 85-90% of patients with AMD. Patients with dry AMD have a substantial risk of developing wet AMD. The formation of drusen, an extracellular, amorphous deposit of material on Bruch's membrane in the macula of the retina, occurs early in the course of the disease. Macular soft drusen are a hallmark of dry AMD.
Currently, there are no animal models that can be used to test pharmacological efficacy of drugs that are under development for treating dry AMD. Thus, an animal model that focuses on drusen formation could be useful. Mice and rats do not have a macula and do not develop drusen. However, our studies of young versus old mice have clearly shown that there is an age-related accumulation of proteins on Bruch's membrane in these rodents (Wang, Lukas, Yuan, Du, Tso, et al., 2009 ). Many of these proteins that build up on Bruch's membrane with age are proteins that are also found in human drusen (Wang, Lukas, Yuan, Du, Tso, et al., 2009 ). Thus, while we agree that mice do not develop ''human-like drusen", we offer the thought that mice do build up ''drusen-like material" (accumulation of proteins) with age on Bruch's membrane. We believe that the buildup of proteins on Bruch's membrane in mice can serve as a surrogate endpoint for the study of drugs that may have the potential to alter the course of drusen formation in humans and, therefore, be of benefit for the treatment of dry AMD.
In the last few years, there has been great progress in producing transgenic mice with various pathological aspects of AMD. Mouse models that have been claimed to develop features of AMD include Ccl2/Ccr2 (Ambati et al., 2003) , cfh (Coffey et al., 2007) , sod1 (Imamura et al., 2006) , sod2 (Justilien et al., 2007) , Ccl2/cx3xr1 (Tuo et al., 2007) , apoE4 (Malek et al., 2005) , Elovl4 (Karan et al., 2005) , Cp/Hp (Hahn et al., 2004) , cathepsin D (Rakoczy et al., 2002) , Rdh8-Abca4 (Maeda et al., 2009) , apoB100 (Fujihara, Bartels, Nielsen, & Handa, 2009 ) and Mdm1 (Ding et al., 2008) . Some of the mouse models have defects that interfere with functions of the RPE, such as cathepsin D (Rakoczy et al., 2002) and others have defects in pathways involved in inflammation, such as Ccl2/cx3cr1 (Tuo et al., 2007) . In many of these models, buildup of proteins on Bruch's membrane has been reported (Malek et al., 2005) . What many of these models have in common is that the AMD features, (Malek et al., 2005) . Specifically, apoE4 mice carrying a targeted knock-in of the human apoE e4
(apoE4) gene that are aged over 18 months and fed a HFD diet for 8 weeks develop pathological features similar to the morphologic hallmarks observed in both dry and wet human AMD.
Our preliminary results demonstrated that the RPE/choroid of apoE4 mice have deposits of proteins surrounding Bruch's membrane at 18-24 months of age. However, we were challenged by the difficulty to do a pilot study over 18-24 months to find any indication of efficacy for pharmacological approaches. Thus, we sought a surrogate model for the buildup of proteins on Bruch's membrane, with the advantage of reporting robust, at least semiquantitative results, in a much more rapid time frame.
The use of transgenic mice as models of AMD to study pharmacological efficacy has limitations. Genes which have been knocked out or knocked down in transgenic animals may be part of the pathway on which the test drug works. For example, if one were to attempt to affect drusen formation using a drug which modulates the immunological system in the CCL2, CCL2-CX3CR1 transgenic animals, which have defects that limit the infiltrative activities of leukocytes in the RPE/choroid, the test drug would be seen as ineffective. However, the lack of efficacy would be because of the genetic manipulations to produce the transgenic animals. As another example, the SOD1 knockout mice need a time course of 12-15 months for degeneration of the RPE and formation of drusen-like material. However, the study of pharmacological anti-oxidants in this model would be complicated by the absence Fig. 1 . Intracellular proteins found in Bruch's membrane from AMD patients, smoking mice, old mice and apoE4 AMD model mice. A and B, an example of CD63 (arrow) in drusen from AMD patients (B), but not in an age-matched controls (A). C and D, an example of aB crystallin (arrows) found in drusen from AMD patients (D), but not in agematched controls (C). E and F, CD63 was found on Bruch's membrane (arrows) of smoking mice (F), but not in age-matched controls (E). G and H, aB crystallin was found on Bruch's membrane (arrows) of smoking mice (H), but not in age-matched controls (G). I and J, CD63 was found on Bruch's membrane (arrows) of 24 mos old mice (J), but not in 4 mos old mice (I). K and L, aB crystallin was found on Bruch's membrane (arrows) of apoE model mice (L), but not in age-matched controls (K). ND, normal diet. HFD, high fat, cholesterol-rich diet.
of SOD1 and artifactually high free radical levels. Thus, the use of transgenic mice for pharmacological studies is made complicated by the genetic manipulation used to create the model.
The strongest known risk factors for AMD are advanced age, smoking (Khan et al., 2006; Thornton et al., 2005; Clemons, Milton, Klein, Seddon, & Ferris, 2005) and genetic factors (Hageman et al., 2005; Li et al., 2006) . Smoking is a primary risk factor associated with the prevalence, incidence and development of dry and wet AMD (Schmidt et al., 2006; Scott et al., 2007; Hughes et al., 2007; Chakravarthy et al., 2007) . Findings from epidemiological studies indicate that smokers were more likely to develop AMD at a substantially younger age (Mitchell, Wang, Smith, & Leeder, 2002) . Furthermore, Klein, Klein, & Moss. (1998) found that there was a significant increase in the age-adjusted incidence of developing large soft drusen with increasing number of pack-years smoked in both men and women (Klein et al., 1998) . Thus, smoking makes old individuals more susceptible to developing AMD and also lowers the age of onset of AMD.
''Smoking mice" can be considered as a model of the buildup of drusen-like material on Bruch's membrane over a relatively short time course. The smoking mice model can be established using previously described methods (Wang, Lukas, Yuan, Du, Handa, et al., 2009; Fujihara, Nagai, Sussan, Biswal, & Handa, 2008) . Briefly, at 8 weeks of age, mice are placed into a smoking chamber for 5 h/day, 5 days/week for 6 months. This chamber contains a smoking machine (Model TE-10, Teague Enterprises, Davis, CA) that burns five cigarettes at a time (2R4F reference cigarettes, 2.45 mg nicotine/cigarette; Tobacco Research Institute, University of Ky). Eight puffs per minute of 2 s duration at a flow rate of 1.05 l/min provide a standard puff of 35 cm 3 . The machine is adjusted to produce side stream (89%) and mainstream smoke (11%). The chamber atmosphere is monitored to maintain total suspended particulates at 90 mg/m 3 , and carbon monoxide at 350 ppm. At the rate indicated above, the entire volume of the chamber is exposed to the equivalent of 32 cigarettes per hour. Control mice are kept in filtered air environment. The exposure chamber has room for 8 standard mouse cages (5 mice/cage). The smoking machine contains two mouse exposure chambers so that 80 mice can be exposed to smoke at the same time.
There have been relatively few studies of the RPE/choroid in smoking mice. Mice exposed to chronic cigarette smoke develop features of early AMD (Wang et al., 2009a) . These mice do not develop choroidal neovascularization that is characteristic of the later ''wet" AMD. Our findings are consistent with the hypothesis that cigarette smoke may accelerate age-related changes in the RPE/ choroid (Wang et al., 2009a; Fujihara et al., 2008; Schmidt et al., 2006; Scott et al., 2007; Hughes et al., 2007; Chakravarthy et al., 2007) .
Smoking mice develop evidence of oxidative damage with degeneration of the RPE and Bruch's membrane (Fujihara et al., 2008) . Smoking mice have strong immunolabeling for 8-OHdG in RPE cells, indicating DNA damage. Most of the DNA damage in the RPE/choroid is to mtDNA (Wang et al., 2009a) , as has been shown in other tissues (Backer & Weinstein, 1980 ). Bruch's membrane is thicker in mice exposed to cigarette smoke compared to mice raised in room air. In the RPE/choroid of smoking mice, there are ultrastructural changes, including a loss of basal infoldings, an increase in intracellular vacuoles, basal laminar deposits, increased outer collagenous layer deposits, increased basal laminar deposit continuity and evidence of damaged mitochondria (Wang et al., 2009a; Fujihara et al., 2008) . TUNEL assays show a higher percentage of apoptotic RPE cells in smoking mice compared to mice raised in room air (Fujihara et al., 2008) .
We have found that the RPE/choroid of smoking mice have similar deposits of proteins surrounding Bruch's membrane at 8 months of age as do normal, aged mice and apoE4 AMD model mice, both of which take 18-24 months to accumulate this material. Using immunohistochemistry, we found exosome marker protein CD63 and chaperone protein aB crystallin between RPE and choroid in AMD patients, but not in age-matched controls (Fig. 1A-D) . CD63 and aB crystallin were found on Bruch's membrane from 8 months old smoking mice which were exposed to cigarette smoke for 6 months, but not in age-matched controls (Fig. 1E-H) . Similarly, CD63 was found in normal aged mice (24 months old) (Fig. 1I and J) and aB crystallin was found in apoE4 mice fed with HFD, but not in control mice (Fig. 1K and L) . Thus, in smoking mice that are 8 months of age, there is accumulation of proteins on Bruch's membrane that are found in human drusen in patients with AMD.
To investigate the mechanism underlying the changes in the RPE in smoking mice, we examined the effects of Benzo(a)Pyrene (B(a)P), a toxic compound in cigarette smoke, on functions of cultured human RPE cells . After exposure to 10 uM B(a)P for 24 h, ARPE-19 cells exhibited an accumulation of damaged Fig. 2 . Protein levels of drusen components in the RPE/choroid of AMD model mice from control and pharmacologically treated mice were determined using specific antibodies against bS crystallin, aB crystallin, fibronectin, ubiquitin and moesion. As shown in A, the western blots for two control animals (lanes 1 and 2) were positive for bS crystallin, aB crystallin, fibronectin, ubiquitin and moesin. However, pharmacologically treated mice (lanes 3-7) had significantly less bS crystalline and aB crystalline. Fibronectin, ubiquitin and moesion were not consistently affected by the pharmacological treatment. In B, the differences in expression levels were determined by multiple scans of blots to ensure a maximum and minimum response range for the measured areas and the integrated areas of the bands were calculated by using Image-J software. Data are expressed as normalized ratios (Control = 1). There were significant decreases in RPE/choroid of bS crystallin and aB crystallin (p < 0.05) in the pharmacologically treated group, compared to the control group. There was no statistically difference in fibronectin, ubiquitin or moesion between treated and control groups (p > 0.05). Values are the mean ± SEM. Appropriate background subtraction and normalization of the data to actin were done for each blot. mitochondrial DNA (Wang et al., 2009a) ; whereas, nuclear DNA was not affected. There was an increase in lysosomal enzyme activity, but the phagocytoic activity of the RPE cells was unaffected. Complement components (C3, CFH) and selected exosomal markers were upregulated after 24 h of B(a)P exposure (Wang et al., 2009a) .
These changes are consistent with those found in vivo in the RPE/choroid of mice exposed to chronic cigarette smoke. These mice exhibit mtDNA damage, increased exocytotic activity and activation of the complement pathway, similar to what we had seen previously with aging and AMD (Wang, Lukas, Yuan, Du, Handa, et al., 2009; Wang, Lukas, Yuan, Du, Tso, et al., 2009 ). Our findings link B(a)P and cigarette smoke with mtDNA damage, altered lysosomal activity, increased exocytotic activity and complement activation in the mouse RPE/choroid. Importantly, changes in the RPE/choroid that are present in aged mouse eyes (24 months) occur at an earlier age (8 months) after exposure to cigarette smoke (Wang, Lukas, Yuan, Du, Handa, et al., 2009) .
We believe that smoking mice provide an experimentally generated phenotype in the RPE/choroid that is relevant to drusen formation in dry AMD. These mice can make possible the necessary preclinical studies that cannot be carried out in humans and be used for screening of pharmacological agents that may be effective in treating dry AMD. The RPE/choroid of smoking mice has similar deposits of material on Bruch's membrane at 8 months of age as in human drusen. Our data show CD63, CD81, LAMP2, C3a, C5 and C5b-9 accumulation on Bruch's membrane (Wang et al., 2009a) . Human drusen contains many other proteins, such as crystallins, tubulin, enolase, ubiquitin, fibronectin, moesin and vimentin that can be monitored. Because of this reduced time frame, using the smoking mouse model will be a significant advantage for testing drugs or other therapies that may modulate the buildup of drusen-like deposits.
In order to do pharmacological studies, one needs a robust and at least semi-quantitative endpoint. Western blot and immunohistochemistry can provide these endpoints in the smoking mice model of drusen-like protein accumulation. Western blot is a semi-quantitative analytical technique used to detect specific proteins in a given sample of tissue homogenate or extract. As an endpoint in a pharmacological experiment, Western blot can be used to compare drug efficacy with the control for the ability of a pharmacological agent to decrease amounts of specific proteins in the tissue. In Fig. 2 , we show preliminary results of such an experiment. As shown in Fig. 2A , the western blots for two untreated (control) animals (animals/lanes 1 and 2) were positive for bS crystallin, aB crystallin, fibronectin, ubiquitin and moesin. However, pharmacologically treated mice (animals/lanes 3-7) had significantly less bS crystalline and aB crystalline. Fibronectin, ubiquitin and moesion were not consistently affected in mice by the pharmacological treatment (Fig. 2B) . Notably, all mice did not respond similarly to the pharmacological treatment; thus, the need to use groups with n = 10 or more mice. Immunohistochemistry is a semi-quantitative, visible, analytical technique to locate the accumulation of protein deposits on Bruch's membrane and verify that pharmacological treatment has indeed led to decreased accumulation of proteins on Bruch's membrane. Fig. 3 demonstrates efficacy Fig. 3 . To observe the pharmacological effects, the tissue locations of certain proteins were visualized by immunohistochemistry with specific antibodies to bS crystallin, aB crystallin, fibronectin, ubiquitin and moesin. There were markedly less depositions of drusen-like proteins on Bruch's membrane in the pharmacologically treated group, compared with the control group. Pharmacological treatment demonstrated efficacy to decrease the accumulation of bS crystallin, aB crystallin, fibronectin, ubiquitin and moesion on Bruch's membrane. Overall, 3/3 mice (six eyes) had decreased bS crystallin, aB crystallin and fibronectin, and 2/3 mice (four eyes) had decreased moesin and polyubiquitin. The examples shown in this figure were chosen from mice in which the pharmacological treatment decreased the accumulation of the five marker proteins on Bruch's membrane. of the pharmacological treatment to decrease the accumulation of bS crystallin, aB crystallin, fibronectin, ubiquitin and moesion on Bruch's membrane.
Thus, in a study of pharmacological modulation of accumulation of proteins on Bruch's membrane, not all proteins and not all mice will demonstrate efficacy to a lead compound. Different pharmacological treatments may alter the accumulation of specific proteins differently. Therefore, a panel of proteins, perhaps 15-20, will be needed to properly assess pharmacological efficacy.
Additional studies using Western blot and immunohistochemistry can determine whether the buildup of deposits on Bruch's membrane in the smoking mouse contains an even wider variety of other proteins found in drusen. Consistent findings from such studies can be made into a panel of protein markers that can be followed by Western blot and immunohistochemistry over time as indicators of the buildup of drusen-like material. Pharmacological treatment of smoking mice that leads to less buildup of a panel of these proteins on Bruch's membrane, as determined by Western blot and immunohistochemistry, may indicate preclinical efficacy for a drug to treat dry AMD.
In summary, we propose using the accumulation of drusen-like protein material on Bruch's membrane in mice as a surrogate endpoint to study pharmacological manipulation of the course of drusen formation. We further propose that such studies using smoking mice can lead to ''proof of concept" for pharmacological agents in a model more relevant to dry AMD than using transgenic mice models of AMD. We believe that pharmacological approaches to modulating the accumulation of drusen-like material using smoking mice may identify drugs that are beneficial for the treatment of dry AMD.
